Results 171 to 180 of about 3,377,134 (229)

Positive inotropic effects of glucose-dependent insulinotropic polypeptide in the human atrium and the mouse atrium. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Neumann J, Hofmann B, Gergs U.
europepmc   +1 more source

Oral GLP‐1RA TERN‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies

Obesity, Volume 34, Issue 9, Page 1742-1758, September 2026.
ABSTRACT Objective The safety, tolerability, pharmacokinetics, and efficacy of TERN‐601, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, were studied in Phase 1 and 2 clinical studies. Methods The Phase 1 (28‐day) and Phase 2 (12‐week), randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies ...
W. Timothy Garvey, Julio Rosenstock, Harold E. Bays, Douglas Denham, Anita Kohli, Melanie Haines, Christopher Jones, Ellen Kwan, Erin Castelloe, Tonya Marmon, Emil Kuriakose, Cara Nelson   +11 more
wiley   +1 more source

Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. [PDF]

J Med Chem
Wu B, Falsey JR, Netirojjanakul C, Herberich B, Holder JR, Sham K, Aral J, Forsythe N, Walker KW, Lu SC, Hager T, Stanislaus S, Komorowski R, Atangan L, Achmatowicz M, Romanini D, Weeraratne D, Miranda LP, Véniant MM, Cheng Y.   +19 more
europepmc   +1 more source

Dual Glucagon and GLP‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8242-8253, September 2026.
ABSTRACT Aims This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
Elif I. Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla Martinez, Anita M. Hennige, Corinna Schoelch   +5 more
wiley   +1 more source

Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism. [PDF]

Cell Metab
Hansford R, Buller S, Tsang AH, Benoit S, Roberts AG, Erskine E, Brown T, Pirro V, Reimann F, Harada N, Inagaki N, Samms RJ, Broichhagen J, Hodson DJ, Adriaenssens A, Park S, Blouet C.   +16 more
europepmc   +1 more source

Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8072-8083, September 2026.
ABSTRACT Aims Tirzepatide is a once‐weekly glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity ...
Nasreen Alfaris, Robert F. Kushner, Jianghao Li, Kevin L. Chen, Mia Fenimore, Boris Calderon, Adam Stefanski   +6 more
wiley   +1 more source

Dual-Targeted Glucose-Dependent Insulinotropic Polypeptide-Loaded Photothermal Nanoparticles to Prevent Obesity via Lipolysis and Browning of White Adipose Tissue. [PDF]

Small Sci
Xie T, Zhao L, Pei S, Wen K, Fei S, Chen W, Li Z, Zhang L, Li L, Guo L, Huang H, Pan Q.   +11 more
europepmc   +1 more source

Effects of Incretin‐Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat‐Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7737-7751, September 2026.
ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Laura Busk‐Cirera, Ida Ørum Carlsen, Lærke Bruun Madsen, Rasmus Michael Sandsdal, Emma Jensen, Simon Birk Kjær Jensen, Signe Sørensen Torekov   +6 more
wiley   +1 more source

Decoding the impact of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist on cardiometabolic health: inflammatory mediators at the focus. [PDF]

Diabetol Metab Syndr
Cheng F, Niu X, Wang Y, Yang F, Yang K, Li W.   +5 more
europepmc   +1 more source

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8367-8377, September 2026.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos, Tina Thethi, Clare J. Lee, Lisa M. Neff, Adam Stefanski, Dachuang Cao, Angel Rodriguez, Amy Bartee   +7 more
wiley   +1 more source